All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Francesc BoschThe virtual Lymphoma Hub Satellite Symposium, at this year's European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, brought together an international panel of experts to discuss the management and treatment of patients with relapsed and/or refractory (R/R) lymphoma. Here, Professor Francesc Bosch, University Hospital Vall d'Hebron, Barcelona, ES, outlines how he would manage a patient with R/R chronic lymphocytic leukemia (CLL) following relapse to venetoclax + rituximab.
Satellite Symposium | Patient with R/R CLL— European perspective
Professor Francesc Bosch discusses the mechanisms of progression under venetoclax, and predictive biomarkers for prognosis following targeted therapy. He recommends transition to Bruton's tyrosine kinase (BTK) inhibitor therapy for the selected patient case, and highlights the value of ibrutinib treatment in patients with R/R CLL previously treated with venetoclax in the MURANO study.
Francesc Bosch also discusses the potential benefit of treatment with Pi3K inhibitors and experimental chimeric antigen receptor (CAR) T-cell therapy in patients with R/R CLL who have received prior venetoclax.
Satellite Symposium | Patient with R/R CLL— European perspective
If you would like to download the slides from Francesc Bosch's presentation, click below.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?